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Introduction: The development of thrombocytopenia after a dose increase in losartan and subsequently after
switching the patient to valsartan is reported.
Case presentation: A 61-year-old Caucasian man presented with epistaxis and gingival bleeding of three weeks
duration. Laboratory evaluation revealed a hemoglobin level of 144g/L, a leukocyte count of 16.2×109 cells/L
(72.51% neutrophils, 20.1% lymphocytes, 6.8% monocytes, 0.4% eosinophils, 0.2% bands), and a platelet count of
15.0×109 cells/L. Flow cytometry of his peripheral blood showed normal CD4:CD8 ratio and no evidence of any
lymphoproliferative disorder. A peripheral smear showed decreased platelets with a few areas of clumping. Four
weeks before presentation to the emergency room, his losartan dose was increased to 100mg once daily due to
continuously elevated blood pressure readings. He had been maintained on losartan 50mg once daily for five years
and previous routine laboratory measurements revealed a baseline platelet count of 248.0×109 cells/L.
The patient began receiving an oral prednisone taper and his platelet count returned to a stable value of >200×109
cells/L. Because there was no other probable cause, he was thought to have developed immune thrombocytopenia
from the increased losartan dose. Losartan was discontinued and one week later he was switched to valsartan
160mg once daily.
Forty-seven days after starting valsartan, the patient presented once again to the emergency room with
intermittent epistaxis and gingival bleeding while brushing his teeth of two weeks duration. Laboratory
measurement revealed a platelet count of 37×109 cells/L. Valsartan was held and another prednisone taper was
initiated. The patient’s platelet count recovered upon valsartan discontinuation and in four weeks, his platelet count
improved to 214×109 cells/L.
Conclusions: A 61-year-old Caucasian man developed immune thrombocytopenia after an increase in losartan
dose and developed immune thrombocytopenia again after he was switched to valsartan.
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Drug-induced thrombocytopenia (DIT) is a phenomenon
that is most frequently associated with heparin, but it has
been attributed to many other agents. Clinicians often
discontinue all medications when a patient presents with
thrombocytopenia, making it difficult, if not impossible, to
determine the causative agent when platelet counts
improve [1]. This has resulted in an exhaustive list of drugs
reported to cause thrombocytopenia despite an estimated
incidence of DIT of <1% in patients receiving medications* Correspondence: Dhiren.patel1@mcphs.edu
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reproduction in any medium, provided the orexcluding heparin [1]. In this report, we describe the case
of a patient who developed thrombocytopenia after an
increase in losartan dose and subsequently upon initiation
of valsartan.
We performed a MEDLINE literature search (1970 to
present) using all possible combinations of the following
key words: ‘angiotensin’, ‘thrombocytopenia’, ‘thrombocyto-
paenia’, ‘thrombopenia’, ‘azilsartan’, ‘candesartan’, ‘eprosartan’,
‘irbesartan’, ‘losartan’, ‘olmesartan’, ‘telmisartan’, and ‘valsar-
tan’. Our search revealed only one case report in the litera-
ture published by Ada et al. in 2002 in the Annals of
Internal Medicine [2]. This was a case of an 82-year-old
woman who presented with epistaxis and easy bruising of
two weeks duration. Two weeks before presentation shed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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switched to losartan. Her only other medications were
nortriptyline and bumetanide, both of which she had
taken for two years. Her platelet count returned to normal
within one week after discontinuing losartan [2].
In addition to our MEDLINE search, we reviewed the pre-
scribing information for all commercially available angioten-
sin II type 1 receptor blockers (ARBs) in order to capture
cases of possible ARB-induced thrombocytopenia that have
not been described in the literature. Currently there are eight
ARBs available for use in the United States: azilartan
(Edarbi™), candesartan (Atacand™), eprosartan (Teveten™),
irebesartan (Avapro™), losartan (Cozaar™), olmesartan
(Benicar™), telmisartan (Micardis™), and valsartan (Diovan™)
[3-10]. One patient receiving candesartan and four patients
receiving eprosartan were withdrawn from clinical trials after
developing thrombocytopenia [4,5]. Thrombocytopenia has
been reported as part of postmarketing surveillance for
irbesartan and telmisartan, but the incidence has not been
described [6,9]. Thrombocytopenia has been reported as part
of postmarketing surveillance for valsartan and losartan but
has been ‘reported rarely’ [7,10]. There have been no cases of
thrombocytopenia described in the prescribing information
for azilsartan and olmesartan [3,8]. Given this limited
information, the incidence of probable ARB-induced
thrombocytopenia is unclear.Case presentation
A 61-year-old, 116kg, 71 inch Caucasian man presented to
the emergency room with epistaxis and gingival bleeding
of three weeks duration. Upon physical examination, no
other gross bleeding was apparent and he denied a history
of similar bleeding events. He was hemodynamically stable,
alert and oriented, and in no acute distress. Results of his
heart and lung examinations were unremarkable. Labora-
tory evaluation revealed a hemoglobin level of 144g/L, a
leukocyte count of 16.2×109 cells/L (72.51% neutrophils,
20.1% lymphocytes, 6.8% monocytes, 0.4% eosinophils,
0.2% bands), and a platelet count of 15.0×109 cells/L. Flow
cytometry of his peripheral blood showed normal CD4:
CD8 ratio and no evidence of any lymphoproliferative
disorder. A peripheral smear showed decreased platelets
with a few areas of clumping. Four weeks before presenta-
tion, his losartan dose was increased to 100mg once daily
due to continuously elevated blood pressure readings. He
had been maintained on losartan 50mg once daily for five
years and previous routine laboratory testing revealed a
baseline platelet count of 248.0×109 cells/L.
The patient began receiving an oral prednisone taper and
his platelet count returned to a stable value of >200×109
cells/L (Figure 1). Because there was no other probable
cause, he was thought to have developed immune
thrombocytopenia from the increased losartan dose.Losartan was discontinued and one week later he was
switched to valsartan 160mg once daily.
This patient’s past medical history was significant for pri-
mary hypertension, uncontrolled type 2 diabetes mellitus,
gastroesophageal reflux disease, post-traumatic stress
disorder, depression, bipolar disorder, and dyslipidemia.
His past surgical history included splenectomy, right
hand skin graft, ventral hernia repair, and a gunshot
wound to the back of the neck. The patient had no prior
history of hematologic abnormalities or vascular disease.
His hepatic and renal functions were normal and stable.
His medications included losartan 100mg once daily
(increased from 50mg once daily four weeks before
presentation), aspirin 325mg once daily, metformin
1000mg twice daily, atenolol 75mg once daily, simvastatin
20mg once daily, ranitidine 150mg twice daily, Novolin™
70/30 insulin 75 units subcutaneously every morning and
85 units every evening, temazepam 15 to 30mg daily as
needed at bedtime, and a multivitamin daily. He had been
taking all of these medications for at least five years. He
has no known drug allergies, but had a documented cough
with lisinopril. The patient had no history suggestive of
infection and no history of chemotherapy, radiation, or
malignancy. He denied alcohol, tobacco, or illicit drug
use and any sexually transmitted disease risk factors. He
denied any family history of any bleeding diatheses.
Forty-seven days after starting valsartan, the patient
presented once again to the emergency room with inter-
mittent epistaxis and gingival bleeding while brushing his
teeth of two weeks duration. Laboratory measurement
revealed a platelet count of 37×109 cells/L. Valsartan
was held and another prednisone taper was initiated.
The patient’s platelet count recovered upon valsartan
discontinuation and in four weeks, his platelet count
improved to 214×109 cells/L (Figure 2). To date, the
patient’s platelet count has remained normal on follow-up
evaluations.
Discussion
A clear correlation exists between the two episodes of
thrombocytopenia and ARB use in our patient. During
his initial hospitalization, only his insulin doses were
adjusted and no new agents were initiated. The patient had
no other conditions associated with thrombocytopenia
and had an unremarkable past medical history for
bleeding or thrombocytopenia. At first, it was thought
that thrombocytopenia was a result of losartan since his
platelet count decreased after the dose was increased
and his platelet count recovered when the drug was
discontinued. However, there was further evidence for this
reaction when the patient was switched to an alternative
ARB, valsartan, and his platelet count decreased again.
When valsartan was discontinued, his platelets returned























Days after discontinuing losartan
Figure 1 Platelet count following discontinuation of losartan.
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ment indicated a score of nine for this patient’s experience
with ARBs [11]: thrombocytopenia occurred after either
ARB was administered (+2); thrombocytopenia improved
after either ARB was discontinued (+1); thrombocytopenia
recurred when another ARB was administered (+2); no
alternate causes on their own could have caused the reac-
tion (+1); thrombocytopenia was more severe when the
dose of losartan was increased (+1); thrombocytopenia
occurred in a previous exposure to an ARB (+1); and
thrombocytopenia was confirmed by objective evidence
(that is, platelet count) (+1). As only one case report of
ARB-induced thrombocytopenia has been reported in the
literature and since the information on causality in the
prescribing information is lacking, we opted for a conser-
vative approach and did not add an additional point for
the existence of conclusive reports of this reaction. Never-
theless, scores ≥9 using this algorithm are indicative of a
definite association between the adverse reaction and the
suspected drug [12].
In addition, we evaluated the casual relationship between
ARB use and thrombocytopenia using a scale developed
by George et al. that specifically evaluates the likelihood
of DIT [13]. The four criteria of this scale are: 1) drug
administration preceded thrombocytopenia; recovery from























Figure 2 Platelet count following discontinuation of valsartan.was discontinued, 2) other drugs administered prior to
thrombocytopenia were continued or reintroduced after
discontinuation of the suspected drug, 3) other etiologies
of thrombocytopenia were excluded, 4) re-exposure to the
drug resulted in recurrent thrombocytopenia. Because all
four of these criteria were met in our patient, this would
be a case of definite DIT.
There is a great deal of similarity between this case
and the other existing case report of ARB-induced
thrombocytopenia reported by Ada et al. 10 years ago
[2]. Both patients presented with similar symptoms with
laboratory results demonstrating thrombocytopenia that
could only be attributed to ARB use. What differentiates
our case is that the initial thrombocytopenic event was
triggered by doubling the dose of losartan; there was no
initial adverse reaction when our patient started losartan
more than five years before. Because of the nephroprotective
benefits of ARB therapy in diabetics as an alternative to
an angiotensin-converting enzyme inhibitor [14,15], an
alternative ARB, valsartan, was initiated. However, this
resulted in the second case of thrombocytopenia that was
discovered after the patient presented with similar bleeding
symptoms as the initial event.
DIT is often an immune-mediated reaction and has
many possible explanations [16]; however, accelerated
platelet destruction caused by drug-dependent antibody23 30 37 44 51
ontinuing valsartan
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In the presence of a sensitizing drug, drug-dependent
antibodies develop that are highly specific to the drug’s
structure approximately one to two weeks after drug
exposure [17]. These drug-dependent antibodies react
with platelets via their fragment antigen-binding (Fab)
domains, rather than their fragment crystallizable (Fc)
domains [16]. This is in contrast to other immune-complex
reactions, such as in heparin-induced thrombocytopenia
where heparin-dependent antibodies react with platelets
via their Fc domain, eventually resulting in thrombotic
complications despite a low platelet count [18]. It is
unknown why these drug-dependent antibodies target
platelets instead of other cells such as leukocytes or
erythrocytes [17].
Losartan was the prototype for the ARB class and was
followed by valsartan; the only structural difference being
replacement of the imidazole of losartan with an acylated
amino acid [19]. Aside from this structural difference,
losartan and valsartan have similar pharmacologic and
pharmacokinetic profiles [19]. It is unclear whether anti-
body cross-reactivity is possible with losartan and valsartan;
however, because their chemical structures are more similar
compared with later ARBs such as telmisartan, it cannot
be ruled out as a possibility.
Because of the very low reported incidence of ARB-
induced thrombocytopenia, routine monitoring of platelets
is probably not necessary. However, ARBs should be eval-
uated as potential causative agents in patients who present
with idiosyncratic thrombocytopenia and are receiving
ARB therapy. Based on our case, if a patient develops
thrombocytopenia thought to be related to an ARB,
the ARB should be discontinued, and an alternative
antihypertensive agent, outside of the ARB class, should be
initiated. Furthermore, patients should always be encour-
aged to report any signs of easy bruising or spontaneous
bleeding when taking any drug, as these may be an early
indication of DIT.Conclusions
A 61-year-old Caucasian man developed immune throm-
bocytopenia after an increase in losartan dose and developed
immune thrombocytopenia again after he was switched to
valsartan.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Competing interests
The authors declare that they have no competing interests.Authors’ contributions
All authors were equally responsible for data collection and writing of the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
The authors would like to thank Matthew L. Romo, PharmD for providing
editorial support.
Author details
1VA Boston Healthcare System, 940 Belmont Street, Brockton, MA 02301,
USA. 2Massachusetts College of Pharmacy and Health Sciences, 179
Longwood Avenue, Boston, MA 02115, USA. 3VA Boston Healthcare System,
150 South Huntington Avenue, Boston, MA 02130, USA.
Received: 12 February 2013 Accepted: 28 May 2013
Published: 15 July 2013
References
1. Zondor SD, George JN, Medina PJ: Treatment of drug-induced
thrombocytopenia. Expert Opin Drug Saf 2002, 1:173–180.
2. Ada S, Yalamanchili M, Friedenberg W: Immune thrombocytopenia after
losartan therapy. Ann Intern Med 2002, 137:704.
3. Edarbi [package insert]. Deerfield, IL: Takeda Pharmaceuticals America,
Inc; 2011.
4. Atacand [package insert]. Wilmington, DE: AstraZeneca, LP; 2012.
5. Teveten [package insert]. North Chicago, IL: Abbott Laboratories; 2012.
6. Avapro [package insert]. New York, NY: Bristol-Myers Squibb Sanofi-Synthelabo
Partnership; 2012.
7. Cozaar [package insert]. Whitehouse Station, NJ: Merck & Co., Inc; 2011.
8. Benicar [package insert]. Parsippany, NJ: Daiichi Sankyo, Inc; 2009.
9. Micardis [package insert]. Ridgefield, CT: Boehringer Ingelheim
Pharmaceuticals, Inc; 2012.
10. Diovan [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2012.
11. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E,
Domecq C, Greenblatt DJ: A method for estimating the probability of
adverse drug reactions. Clin Pharmacol Ther 1981, 30:239–245.
12. Michel DJ, Knodel LC: Comparison of three algorithms used to evaluate
adverse drug reactions. Am J Hosp Pharm 1986, 43:1709–1714.
13. George JN, Raskob GE, Shah SR, Rizvi MA, Hamilton SA, Osborne S,
Vondracek T: Drug-induced thrombocytopenia: a systematic review of
published case reports. Ann Int Med 1998, 129:886–890.
14. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH,
Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators:
Effect of losartan on renal and cardiovascular outcomes in patients with
type 2 diabetes and nephropathy. N Engl J Med 2001, 345:851–869.
15. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J,
Diabetics Exposed to Telmisartan and Enalapril Study Group: Angiotensin-
receptor blockade versus converting-enzyme inhibition in type 2
diabetes and nephropathy. N Engl J Med 2004, 351:1952–1961.
16. Aster RH, Bougie DW: Drug-induced immune thrombocytopenia.
N Engl J Med 2007, 357:580–587.
17. George JN, Aster RH: Drug-induced thrombocytopenia: pathogenesis,
evaluation, and management. Hematology Am Soc Hematol Educ Program
2009, 1:153–158.
18. Warkentin TE, Hayward CP, Boshkov LK, Santos AV, Sheppard JA, Bode AP,
Kelton JG: Sera from patients with heparin-induced thrombocytopenia
generate platelet-derived microparticles with procoagulant activity: an
explanation for the thrombotic complications of heparin-induced
thrombocytopenia. Blood 1994, 84:3691–3699.
19. Burnier M, Brunner HR: Angiotensin II receptor antagonists. Lancet 2000,
335:637–645.
doi:10.1186/1752-1947-7-183
Cite this article as: Patel et al.: Angiotensin II type 1 receptor blocker-
induced immune thrombocytopenia: a case report. Journal of Medical
Case Reports 2013 7:183.
